Entecavir Induced Severe Myopathy: An Uncommon Side Effect
Creators
- 1. Department of Internal Medicine, Gastroenterology, Sancaktepe Şehit Profesör İlhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey.
- 2. Department of Family Medicine, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
Description
Abstract
Chronic Hepatitis B virus (HBV) infection is a chronic viral illness that affects millions of people around the world and can cause serious consequences such as hepatic failure and hepatocellular carcinoma. Entecavir, a guanosine nucleoside analog (NA), is a commonly used and generally safe therapeutic agent in HBV infection. In this paper, we aimed to present a case of chronic HBV that developed severe myopathy as an extremely rare side effect after the use of entecavir. Patients receiving entecavir therapy for chronic HBV should be closely monitored for the development of myopathy as well as other known and common side effects.
Özet
Kronik Hepatit B virusu (HBV) enfeksiyonu, dünya çapında milyonlarca insanı etkileyen ve karaciğer yetmezliği ve hepatoselüler karsinoma gibi ciddi sonuçlara neden olabilen kronik viral bir hastalıktır. Bir guanozin nükleozit analoğu (NA) olan entekavir, HBV enfeksiyonunda yaygın olarak kullanılan ve genellikle güvenli bir terapötik ajandır. Bu yazıda, entekavir kullanımından sonra son derece nadir bir yan etki olarak şiddetli miyopati gelişen bir kronik HBV olgusunu sunmayı amaçladık. Kronik HBV için entekavir tedavisi alan hastalar, miyopati gelişimi ve diğer bilinen ve yaygın yan etkiler açısından yakından izlenmelidir.
Notes
Files
jmvi.2021.26.pdf
Files
(182.6 kB)
Name | Size | Download all |
---|---|---|
md5:d8077a97f836f1ccc4b7ac1911aebffd
|
182.6 kB | Preview Download |
Additional details
References
- 1. Wilkins T, Sams R, Carpenter M. Hepatitis B: Screening, Prevention, Diagnosis, and Treatment. Am Fam Physician 2019; 99(5): 314-23.
- 2. Karagoz E, Tanoglu A. Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection. Hepat Mon 2017; 17(4): e12293.
- 3. Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Demir M, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther 2015; 41(3): 310-9.
- 4. Tu T, Douglas MW. Hepatitis B Virus Infection: From Diagnostics to Treatments. Viruses 2020; 12(12): 1366.
- 5. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve 2015; 51(5): 638-56.
- 6. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354(10): 1001-10.
- 7. Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat 2011; 18(12): 892-6.
- 8. Yuan K, Guochun W, Huang Z, Lin B, Zhou H, Lu X. Entecavir-associated myopathy: a case report and literature review. Muscle Nerve 2014; 49(4): 610-4.
- 9. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci U S A 2001; 98(5): 2284-8.
- 10. Bridges EG, Jiang Z, Cheng YC. Characterization of a dCTP transport activity reconstituted from human mitochondria. J Biol Chem 1999; 274(8): 4620-5.